DDD

Clinical trials for DDD explained in plain language.

Never miss a new study

Get alerted when new DDD trials appear

Sign up with your email to follow new studies for DDD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Not yet finished but already full! 2 Completed 1

Hope for rare kidney patients: new drug shows promise in phase 3 trial

Disease control Completed

This study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage, compared to a placebo. Participants received injections twice a week …

Matched conditions: DDD

Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control

Last updated May 17, 2026 07:24 UTC

DDD

Get alerted when new DDD trials appear

Hope for rare kidney patients: new drug shows promise in phase 3 trial